Bhandari Kalpana, Srinivas Nagarapu, Shiva Keshava G B, Shukla Praveen K
Medicinal and Process Chemistry Division, Central Drug Research Institute, Lucknow 226001, India.
Eur J Med Chem. 2009 Jan;44(1):437-47. doi: 10.1016/j.ejmech.2008.01.006. Epub 2008 Jan 25.
A series of novel (Z)- and (E)-2-imidazolo-/triazolo-methyl tetrahydronaphthyl oxime ethers (7-28) were synthesized as conformationally constrained analogues of oxiconazole and evaluated for antifungal and antibacterial activities. Many of these derivatives exhibited potent antibacterial activity and surprisingly none of them was active against fungal strains. The SAR studies showed that imidazole oxime ethers were more active than the corresponding triazole oxime ethers. Imidazole derivatives 8, 11, 12, 15, 18, 19, 21 and 23 exhibited high inhibitory activity with 1.56-0.39 microg/mL MIC values against Klebsiella pneumoniae, Escherichia coli and Staphylococcus aureus. These compounds represent new structure scaffolds that can be further optimized to give new antibacterial agents with structures significantly different from those of existing classes of antibiotics.
合成了一系列新型的(Z)-和(E)-2-咪唑并/三唑并-甲基四氢萘基肟醚(7-28)作为奥昔康唑的构象受限类似物,并对其抗真菌和抗菌活性进行了评估。这些衍生物中的许多表现出强效抗菌活性,令人惊讶的是,它们均对真菌菌株无活性。构效关系研究表明,咪唑肟醚比相应的三唑肟醚更具活性。咪唑衍生物8、11、12、15、18、19、21和23对肺炎克雷伯菌、大肠杆菌和金黄色葡萄球菌表现出高抑制活性,最低抑菌浓度(MIC)值为1.56-0.39μg/mL。这些化合物代表了新的结构支架,可进一步优化以得到结构与现有抗生素类别显著不同的新型抗菌剂。